Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

IMULDOSA

USTEKINUMAB-SRLF

Standard Dose
130MG/26ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview IMULDOSA is listed in Drugs@FDA under application 761364 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-SRLF Form and strength INJECTABLE;INTRAVENOUS - 130MG/26ML Sponsor ACCORD BIOPHARMA INC.

Structured Monograph

Clinical summary

Approval overview IMULDOSA is listed in Drugs@FDA under application 761364 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient USTEKINUMAB-SRLF Form and strength INJECTABLE;INTRAVENOUS - 130MG/26ML Sponsor ACCORD BIOPHARMA INC. Submission history Latest submission status date: 2025-11-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.